Open AccessTargeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data
Author(s) -
Kirstein Martha M.,
Lange Ansgar,
Prenzler Anne,
Manns Michael P.,
Kubicka Stefan,
Vogel Arndt
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0032
Subject(s) - medicine , regorafenib , bevacizumab , aflibercept , panitumumab , folfiri , cetuximab , oncology , irinotecan , colorectal cancer , sunitinib , ramucirumab , population , cancer , chemotherapy , environmental health
Background. Survival of patients with metastatic colorectal cancer (mCRC) has been significantly improved with the introduction of the monoclonal antibodies targeting the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR). Novel molecular‐targeted agents such as aflibercept and regorafenib have recently been approved. The aim of this review is to summarize and assess the effects of molecular agents in mCRC based on the available phase II and III trials, pooled analyses, and meta‐analyses/systematic reviews. Methods. A systematic literature search was conducted using the meta‐database of the German Institute of Medical Documentation and Information. Criteria of the Scottish Intercollegiate Guidelines Network were used to assess the quality of the controlled trials and systematic reviews/meta‐analyses. Results. Of the 806 retrieved records, 40 publications were included. For bevacizumab, efficacy in combination with fluoropyrimidine‐based chemotherapy in first‐ and subsequent‐line settings has been shown. The benefit of continued VEGF targeting has also been demonstrated with aflibercept and regorafenib. Cetuximab is effective with fluoropyrimidine, leucovorin, and irinotecan (FOLFIRI) in first‐line settings and as a single agent in last‐line settings. Efficacy for panitumumab has been shown with oxaliplatin with fluoropyrimidine in first‐line settings, with FOLFIRI in second‐line settings, and as monotherapy in last‐line settings. Treatment of anti‐EGFR antibodies is restricted to patients with tumors that do not harbor mutations in Kirsten rat sarcoma and in neuroblastoma RAS. Conclusion. Among various therapeutic options, the future challenge will be a better selection of the population that will benefit the most from specific anti‐VEGF or anti‐ EGFR treatment and a careful consideration of therapy sequence.